Found 93 clinical trials
A Study of SGN-B6A in Advanced Solid Tumors
It will also study whether SGN-B6A works to treat solid tumors. The study will have two parts. Part A of the study will find out how much SGN-B6A should be given to participants. Part B will use the dose found in Part A to find out how safe SGN-B6A is …
- 0 views
- 19 Feb, 2024
- 3 locations
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.
- 0 views
- 22 Aug, 2025
- 2 locations
A Study of SY 5609 a Selective CDK7 Inhibitor in Advanced Solid Tumors
This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.
- 0 views
- 19 Feb, 2024
- 5 locations
A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of BPI-1178 in subjects with advanced solid tumor, as well as the subjects with advanced hormone receptor-positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- 0 views
- 19 Feb, 2024
- 1 location
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors
Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.
- 0 views
- 19 Feb, 2024
- 1 location
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- 0 views
- 19 Feb, 2024
- 1 location
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.
- 0 views
- 19 Feb, 2024
- 1 location
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors
A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies
- 0 views
- 19 Feb, 2024
- 7 locations
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …
- 0 views
- 19 Feb, 2024
- 1 location
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications
This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.
- 0 views
- 19 Feb, 2024
- 1 location